BioCentury
ARTICLE | Clinical News

NurOwn: Phase II data

August 15, 2016 7:00 AM UTC

Top-line data from a double-blind, placebo-controlled, U.S. Phase II trial in 48 patients with ALS showed that a single treatment of NurOwn administered by combined intramuscular and intrathecal injec...